- Home
- EQX vs HALO Comparison
EQX vs HALO Comparison
Compare EQX & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EQX | HALO |
|---|---|---|
| Founded | 2007 | 1998 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9B | 7.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | EQX | HALO |
|---|---|---|
| Price | $13.93 | $63.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 12 |
| Target Price | $17.00 | ★ $73.33 |
| AVG Volume (30 Days) | ★ 8.3M | 2.7M |
| Earning Date | 11-05-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 56.68 |
| EPS | 0.11 | ★ 4.74 |
| Revenue | ★ $2,296,356,000.00 | $1,242,852,000.00 |
| Revenue This Year | $78.78 | $32.47 |
| Revenue Next Year | $60.10 | $24.31 |
| P/E Ratio | $175.53 | ★ $13.37 |
| Revenue Growth | ★ 85.65 | 31.19 |
| 52 Week Low | $4.95 | $46.26 |
| 52 Week High | $14.36 | $79.50 |
Technical Indicators
Market Signals| Indicator | EQX | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 66.28 | 33.96 |
| Support Level | $13.62 | $61.70 |
| Resistance Level | $14.27 | $74.25 |
| Average True Range (ATR) | 0.56 | 2.52 |
| MACD | 0.08 | -0.97 |
| Stochastic Oscillator | 84.30 | 13.39 |
Price Performance
Historical ComparisonAbout EQX Equinox Gold Corp.
Equinox Gold Corp is a mining company engaged in the operation, acquisition, exploration, and development of mineral properties, with a focus on gold. Equinox Gold has around seven operating gold mines and a clear plan to increase production by advancing the pipeline of growth projects. Geographically, the company operates in the United States, Mexico, and Brazil. The majority of its revenue is generated from Canada.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.